Documents

A list of downloadable documents created during development.

Review proposal consultation

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): equality impact assessment - guidance development

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): final appraisal determination

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appraisal consultation

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): final scope

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): final matrix

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): response to consultee and commentator comments on the draft scope

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): response to consultee and commentator comments on the provisional matrix

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): scoping EIA form

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appendix B - draft scope for consultation (pre-referral) March 2011

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appendix C - provisional matrix (pre-referral) March 2011